Elevated WAT-1 Scores Indicate Iatrogenic Withdrawal Syndrome in NICU Infants
An elevated WAT-1 score of 3 or higher indicates that the infant is experiencing clinically significant iatrogenic withdrawal syndrome (IWS) from opioids and/or benzodiazepines. This threshold has been validated to identify infants who require intervention to manage withdrawal symptoms 1.
What the WAT-1 Score Means
The Withdrawal Assessment Tool-1 (WAT-1) is an 11-item assessment scale ranging from 0-12 points that monitors withdrawal symptoms in pediatric patients, including NICU infants 1. The tool was specifically designed and validated for assessing iatrogenic withdrawal in critically ill children receiving prolonged opioid and/or benzodiazepine therapy 2, 3.
Score Interpretation:
- WAT-1 score ≥3: Indicates clinically significant withdrawal requiring intervention
- WAT-1 score <3: Suggests withdrawal symptoms are not clinically significant at that time
The tool demonstrates excellent sensitivity (0.872) and specificity (0.880) for detecting withdrawal 2.
Clinical Significance of Elevated Scores
When infants have WAT-1 scores ≥3, research shows they have:
- Greater cumulative opioid exposure: 40.2 mg/kg vs 17.6 mg/kg in those with lower scores 3
- Longer duration of opioid treatment: 7 days vs 5 days before weaning 3
- Prolonged weaning periods: 10 days vs 6 days 3
- Extended ICU stays and mechanical ventilation duration 2
What Symptoms the WAT-1 Captures
The WAT-1 primarily assesses two domains that account for most variance in withdrawal severity 3:
Motor-Related Symptoms:
- Tremors
- Increased muscle tone
- Uncoordinated/repetitive movements
- Hyperactive reflexes
Behavioral State Changes:
- Irritability
- Increased wakefulness
- High-pitched crying
- Poor feeding
Additional Autonomic Signs:
- Sweating
- Fever
- Gastrointestinal dysfunction (loose stools, vomiting)
These symptoms reflect CNS irritability, autonomic overreactivity, and gastrointestinal dysfunction characteristic of opioid and benzodiazepine withdrawal 4.
When to Expect Withdrawal
Risk factors requiring WAT-1 monitoring include:
- ≥5 days of continuous opioid or benzodiazepine infusion 1
- Onset typically occurs 1-48 hours after tapering or discontinuation 1
- Fentanyl and morphine are the most common causative agents in NICU/PICU settings 1
The prevalence of IWS ranges from 35-57% in pediatric ICU patients who received these medications for ≥5 days 1.
Critical Diagnostic Considerations
Before confirming withdrawal, exclude other causes of similar symptoms:
- Pain or distress from underlying illness
- Respiratory distress
- Delirium
- Environmental stress (noise, overstimulation) 1
This is particularly important because these symptoms overlap significantly with withdrawal manifestations, and misdiagnosis could lead to inappropriate treatment.
Management Implications
When WAT-1 scores are ≥3:
- Slow the weaning schedule of opioids/benzodiazepines
- Consider conversion to longer-acting agents (e.g., methadone for opioids) 4
- Implement or optimize non-pharmacologic interventions (swaddling, reduced stimulation, frequent small feedings)
- Continue monitoring with WAT-1 assessments every 4-8 hours or more frequently based on clinical status 1
Important Caveats
- Age considerations: The WAT-1 shows no significant differences in scores across age groups, making it applicable from neonates through adolescents 3
- Preterm infants: May exhibit less severe withdrawal symptoms due to CNS immaturity, but this may also reflect difficulty in assessment rather than true decreased severity 4
- Interrater reliability: Requires consistent nurse training and re-education to maintain accuracy 5
- Continue monitoring: Assess for withdrawal symptoms even after NICU discharge, as symptoms can persist or emerge later 1
The WAT-1 provides objective, standardized assessment that facilitates targeted intervention and prevents both under-treatment and over-treatment of iatrogenic withdrawal in vulnerable NICU infants.